zanubrutinib + obinutuzumab + CVP

This therapy is a **combination regimen** that includes zanubrutinib, obinutuzumab, and CVP (cyclophosphamide, vincristine, prednisone). It is being investigated primarily for the treatment of **follicular lymphoma**, especially in previously untreated patients[1][2]. **Zanubrutinib** is a next-generation small molecule inhibitor targeting Bruton tyrosine kinase (BTK), designed for selectivity and reduced off-target effects, resulting in the inhibition of B-cell receptor signaling, which leads to suppression of malignant B-cell proliferation and survival[7]. **Obinutuzumab** is a glycoengineered type II anti-CD20 monoclonal antibody, inducing B-cell depletion through direct cytotoxicity, antibody-dependent cellular cytotoxicity, and complement activation. **CVP** is a standard chemotherapy backbone composed of **cyclophosphamide** (an alkylating agent damaging DNA), **vincristine** (a vinca alkaloid disrupting microtubule formation), and **prednisone** (a corticosteroid with lympholytic effects)[3][6]. The multi-mechanism approach is hypothesized to enhance efficacy over standard regimens by targeting malignant B-cells through diverse biological pathways[1][2].